CoChat
Sign Up
Cited by 97

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF

Jiang, Ying, Rigoglioso, Andrew, Peterhoff, Corrinne M., Pawlik, Monika, Sato, Yutaka, Bleiwas, Cynthia, Stavrides, Philip, Smiley, John F., Ginsberg, Stephen D., Mathews, Paul M., Levy, Efrat, Nixon, Ralph A.·2016·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2015.11.013PMC PMC4773919
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2015.11.013

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 48

  1. Barman, 2014, Computational insights into substrate and site specificities, catalytic mechanism, and protonation states of the catalytic asp dyad of beta -Secretase, Scientifica (Cairo), 2014, 598728
  2. Cai, 2001, BACE1 is the major beta-secretase for generation of Abeta peptides by neurons, Nat. Neurosci., 4, 233, 10.1038/85064 · DOI
  3. Cataldo, 2008, Down syndrome fibroblast model of Alzheimer-related endosome pathology. Accelerated endocytosis promotes late endocytic defects, Am. J. Pathol., 173, 370, 10.2353/ajpath.2008.071053 · DOI
  4. Cataldo, 2000, Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations, Am. J. Pathol., 157, 277, 10.1016/S0002-9440(10)64538-5 · DOI · Paper page
  5. Chen, 2009, In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model, Neurobiol. Aging, 30, 1453, 10.1016/j.neurobiolaging.2007.11.026 · DOI
  6. Choi, 2009, Age-dependent dysregulation of brain APP in the Ts65Dn Down syndrome mouse model, J. Neurochem., 110, 1818, 10.1111/j.1471-4159.2009.06277.x · DOI · Paper page
  7. Choi, 2013, Early endosomal abnormalities and cholinergic neuron degeneration in amyloid-beta protein precursor transgenic mice, J. Alzheimers Dis., 34, 691, 10.3233/JAD-122143 · DOI
  8. Cossec, 2012, Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes, Hum. Mol. Genet., 21, 3156, 10.1093/hmg/dds142 · DOI
  9. Davisson, 1990, Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome, Prog. Clin. Biol. Res., 360, 263
  10. Davisson, 1993, Segmental trisomy as a mouse model for Down syndrome, Prog. Clin. Biol. Res., 384, 117
  11. Deinhardt, 2006, Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway, Neuron, 52, 293, 10.1016/j.neuron.2006.08.018 · DOI
  12. Devi, 2011, Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice, Neurobiol. Dis., 45, 417, 10.1016/j.nbd.2011.09.001 · DOI
  13. Gouras, 1998, Generation and regulation of beta-amyloid peptide variants by neurons, J. Neurochem., 71, 1920, 10.1046/j.1471-4159.1998.71051920.x · DOI
  14. Granholm, 2000, Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome, Exp. Neurol., 161, 647, 10.1006/exnr.1999.7289 · DOI
  15. Holtzman, 1996, Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome, Proc. Natl. Acad. Sci. U. S. A., 93, 13333, 10.1073/pnas.93.23.13333 · DOI · Paper page
  16. Hunter, 2004, Minocycline prevents cholinergic loss in a mouse model of Down's syndrome, Ann. Neurol., 56, 675, 10.1002/ana.20250 · DOI
  17. Imbimbo, 2008, Therapeutic potential of gamma-secretase inhibitors and modulators, Curr. Top. Med. Chem., 8, 54, 10.2174/156802608783334015 · DOI · Paper page
  18. Jiang, 2010, Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition, Proc. Natl. Acad. Sci. U. S. A., 107, 1630, 10.1073/pnas.0908953107 · DOI
  19. Kaether, 2006, Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface, Traffic, 7, 408, 10.1111/j.1600-0854.2006.00396.x · DOI
  20. Kaur, 2014, Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome, J. Neurosci., 34, 5099, 10.1523/JNEUROSCI.5338-13.2014 · DOI · Paper page
  21. Kim, 2015, Evidence that the Rab5 effector APPL1 mediates APP-βCTF induced dysfunction of endosomes in Down syndrome and Alzheimer's disease, Mol. Psychiatry
  22. Kobayashi, 2008, BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease, Neurobiol. Aging, 29, 861, 10.1016/j.neurobiolaging.2007.01.002 · DOI · Paper page
  23. Laifenfeld, 2007, Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis, J. Neurosci., 27, 7141, 10.1523/JNEUROSCI.4599-06.2007 · DOI
  24. Laird, 2005, BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions, J. Neurosci., 25, 11693, 10.1523/JNEUROSCI.2766-05.2005 · DOI · Paper page
  25. Lee, 2005, BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo, J. Cell Biol., 168, 291, 10.1083/jcb.200407070 · DOI · Paper page
  26. Lockrow, 2009, Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model, Exp. Neurol., 216, 278, 10.1016/j.expneurol.2008.11.021 · DOI
  27. Luo, 2003, Biochemical and genetic evidence for the involvement of yeast Ypt6-GTPase in protein retrieval to different Golgi compartments, J. Biol. Chem., 278, 791, 10.1074/jbc.M209120200 · DOI
  28. McPhie, 2001, beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations, Brain Res. Mol. Brain Res., 97, 103, 10.1016/S0169-328X(01)00294-7 · DOI
  29. Moore, 2010, Increased male reproductive success in Ts65Dn “Down syndrome” mice, Mamm. Genome, 21, 543, 10.1007/s00335-010-9300-8 · DOI
  30. Moore, 2015, APP metabolism regulates tau proteostasis in human cerebral cortex neurons, Cell Rep., 11, 689, 10.1016/j.celrep.2015.03.068 · DOI · Paper page
  31. Nishitomi, 2006, BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice, J. Neurochem., 99, 1555, 10.1111/j.1471-4159.2006.04178.x · DOI
  32. Nixon, 2013, The role of autophagy in neurodegenerative disease, Nat. Med., 19, 983, 10.1038/nm.3232 · DOI · Paper page
  33. Ohno, 2007, BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice, Neurobiol. Dis., 26, 134, 10.1016/j.nbd.2006.12.008 · DOI · Paper page
  34. Pastorino, 2004, BACE (beta-secretase) modulates the processing of APLP2 in vivo, Mol. Cell. Neurosci., 25, 642, 10.1016/j.mcn.2003.12.013 · DOI
  35. Pera, 2013, Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease, Acta Neuropathol., 125, 201, 10.1007/s00401-012-1062-9 · DOI · Paper page
  36. Salehi, 2006, Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration, Neuron, 51, 29, 10.1016/j.neuron.2006.05.022 · DOI · Paper page
  37. Schmidt, 2005, Tissue processing prior to protein analysis and amyloid-beta quantitation, Methods Mol. Biol., 299, 267
  38. Schmidt, 2005, ELISA method for measurement of amyloid-beta levels, Methods Mol. Biol., 299, 279
  39. Seo, 2005, Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice, Exp. Neurol., 193, 469, 10.1016/j.expneurol.2004.11.017 · DOI
  40. Singer, 2005, Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model, Nat. Neurosci., 8, 1343, 10.1038/nn1531 · DOI
  41. Sinha, 1999, Purification and cloning of amyloid precursor protein beta-secretase from human brain, Nature, 402, 537, 10.1038/990114 · DOI · Paper page
  42. Smiley, 2012, Cortical thickness, neuron density and size in the inferior parietal lobe in schizophrenia, Schizophr. Res., 136, 43, 10.1016/j.schres.2012.01.006 · DOI
  43. Tamayev, 2012, Inhibition of gamma-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia, Mol. Neurodegener., 7, 19, 10.1186/1750-1326-7-19 · DOI · Paper page
  44. Tamayev, 2012, beta- but not gamma-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia, EMBO Mol. Med., 4, 171, 10.1002/emmm.201100195 · DOI · Paper page
  45. Tomasselli, 2003, Employing a superior BACE1 cleavage sequence to probe cellular APP processing, J. Neurochem., 84, 1006, 10.1046/j.1471-4159.2003.01597.x · DOI
  46. Villar, 2005, Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12, Mamm. Genome, 16, 79, 10.1007/s00335-004-2428-7 · DOI
  47. Walter, 2001, Phosphorylation regulates intracellular trafficking of beta-secretase, J. Biol. Chem., 276, 14634, 10.1074/jbc.M011116200 · DOI · Paper page
  48. Weissmiller, 2015, A gamma-secretase inhibitor, but not a gamma-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP, PLoS One, 10, e0118379, 10.1371/journal.pone.0118379 · DOI

Cited by

Sorted by citations

Metadata

Authors
Jiang, Y., Rigoglioso, A., Peterhoff, C. M., Pawlik, M., Sato, Y., Bleiwas, C., Stavrides, P., Smiley, J. F., Ginsberg, S. D., Mathews, P. M., Levy, E., & Nixon, R. A.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2016-03
Volume
39
Pages
90-98
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2015.11.013
PMC
PMC4773919
Cited by
97
References
7
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • National Institutes of Health
  • National Institute on Aging (P01AG017617, AG043375)
  • Alzheimer's Association (IIRG-12-237253, IIRG-07-60047)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review